High Potent Medicines Conference: Bringing Solutions to Challenges in Advanced High Potent Medicines (Boston, MA, United States

DUBLIN, July 21, 2023 /PRNewswire/ — The “High Potent Medicines Conference” has been added to  ResearchAndMarkets.com’s offering.

The High Potent Medicines Conference, scheduled for 19th – 20th October 2023, in Boston, USA will evidence the presence of some great minds in the Medical and Pharmaceutical industry bringing you the solutions to the challenges faced in advanced High Potent Medicines. Grab the opportunity to interact with them, 10+ hours of dedicated networking for two days in a row and meet your potential targets to create target revenue.

Looking and the current market scenario, many companies are outsourcing the manufacture of their highly potent compounds for various reasons, mainly marketing.

The escalation in the High Potent drug market is subjected to various aspects such as the diversification of pharmaceutical manufacturers towards precision medicines such as HPAPI, increasing demand for oncology drugs & antibody-drug conjugates, and advancements in HPAPI manufacturing technologies.

Key Highlights

• Process Development and scale-up of HPAPI’s

• Strategies for effective outsourcing partnership

• Containment and Handling Strategies

• Validation of cleaning procedures to avoid cross-contamination

• Regulatory Landscape

• Hazard Assessment Classifications

Why Attend?

• Utilizing the best practices to ensure the safe and efficient production of high potent medicines

• Training sessions on complex high potent compound handling and containment issues

• Understanding the updated regulatory guidelines in the HPAPI process

• Implementing response plans to react to an unplanned event

• Knowing the outsourcing strategies to effectively build a reliable supply chain

Who Should Attend:

From pharmaceutical and Biopharmaceutical manufacturing:

Chief executives, VPs, Directors, Heads, Leaders, Senior Managers, Principal Scientists, Principal Toxicologists, Toxicologists, Fellows, and Investigators working in:

• Research & Development

• Manufacturing/Operations/Production

• Maintenance

• Engineering

• Risk Assessments

• Laboratory Services/Analytical

• New Technologies

• Process Development/Technical transfer

Story continues

Agenda:

Day 1 Thu, 19-Oct-2023

• Registration – 08:00 – 08:50

• Welcome note – 08:50 – 08:55

• Opening Remarks from the Chairperson

• Dean Calhoun, President, CEO, Affygility Solutions, USA – 08:55 – 09:00

IMPLEMENTATION AND INTERPRETATION OF ADVANCED MANUFACTURING PRACTICES IN HPAPI

• Keynote Presentation – Overcoming the Challenges Associated with Containment in HPAPI Manufacturing with Respirator Innovation

• Dean Calhoun, President, CEO, Affygility Solutions, USA – 09:00 – 09:30

• Challenges for Analysts Handling APIs in the Lab

• Senior Representative CTS Europe Ltd., CTS Europe Ltd. – 09:30 – 10:00

• Disinfection/Sterilization Process

• Lila Price, Sterile Processing – Leader, Whitman Partners – 10:00 – 10:30

• Morning Refreshments and Poster Presentation – One-to-One Networking Meetings – 10:30 – 11:15

• Senior Representative FPS, FPS – 11:15 – 11:45

• Pharmaceuticals and the Environment: Impact, Stewardship, and Sustainability

• Kevin Dreher, Senior Scientist (Toxicology), Dreher Toxicology Consulting LLC – 11:45 – 12:15

• Senior Representative BSP Pharmaceuticals, BSP Pharmaceuticals, – 12:15 – 12:45

RISK ASSESSMENTS & DECISION MAKING IN HPAPI

• HPAPI Handling from Lab Bench to Pilot Plant within Chemical Development

• Jayen Diyora, Sr. Manager, Cleaning Validation, Bristol Myers Squibb – 12:45 – 13:15

• Lunch and Poster Presentation – One-to-One Networking Meetings – 13:15 – 14:15

• Process Improvement Through Change Initiatives and Cleaning/Equipment Validation

• Connor Habib, Project Lead, Bristol-Myers Squibb – 14:15 – 14:45

• Panel Discussion: Revealing the Key Concerns of Each Perspective in High Potent Manufacturing and How that Directs their Decision-Making – 14:45 – 15:15

• Revealing Novel PAT Assays for Biologic Detection at the Single Particle Scale to Avoid Cross Contamination – 15:15 – 15:25

• Gauging the Risk in the Cross-Contamination and Reprocessing of Medical and Pharma Devices to Increase Safety & Cost Effectiveness – 15:25 – 15:40

• Afternoon Refreshments and Poster Presentation – One-to-One Networking Meetings – 15:40 – 16:25

• Essential Elements of HPAPI Projects with Respect to Patient Safety and Operator – 16:25 – 16:55

• Applying Our Outmost Understandings with HPAPI Controls to Improve Sustainability, Safety and Efficient Production – 16:55 – 17:25

• Closing Remarks from the Chairperson – 17:25 – 17:30

• Drinks Reception & Networking – 17:30 – 17:30

• End of Day 1 – 17:30 – 17:30

Day 2 Fri, 20-Oct-2023

• Registration – 08:15 – 08:55

• Welcome note – 08:55 – 09:00

• Opening remarks from the Chairman – 09:00 – 09:10

DESIGNING ENGINEERING CONTROLS FOR HIGH POTENCY CONTAINMENT

• Keynote Presentation- Trends and Outlook on Containment – 09:10 – 09:40

• Reserved Slot for Platinum Sponsor – 09:40 – 10:10

• How Should Risk, Hazard, and Uncertainty be Treated with Respect to Containment Controls? – 10:10 – 10:25

• Morning Refreshments and Poster Presentation – One-to-One Networking Meetings – 10:25 – 11:10

• Reserved Slot for Gold Sponsor – 11:10 – 11:40

• Completing and Presenting a Convincing Quantitative Cost-Benefit Analysis and Discovering ALL the benefits of a containment investment in HPAPI – 11:40 – 12:10

• Reserved Slot for Silver Sponsor – 12:10 – 12:40

• A Hygienist’s Perspective in Broadening Facilities to manage exposure/Common Pitfalls in Industrial Hygiene with Highly Potent APIs and the Means to Avoid Them – 12:40 – 13:10

• Lunch and Poster Presentation – One-to-One Networking Meetings – 13:10 – 14:10

EFFECTIVE PLANT DESIGN – A VITAL COMPONENT OF MANUFACTURING

• Exploring Advanced Technology for Next Generation Isolation Design – 14:10 – 14:40

• Uncovering How to Front-Load Facility Design so it goes Hand-in-Hand with Process Development – 14:40 – 14:55

• Reducing the environmental impact with optimized ventilation design – 14:55 – 15:25

• Afternoon Refreshments and Poster Presentation – One-to-One Networking Meetings – 15:25 – 16:05

• Guidelines and Practices for the most cost-effective large-scale production of HPAPI products – 16:05 – 16:35

• Ventilation requirements for occupational hygiene exposure – 16:35 – 17:05

• Closing Remarks from the Chairman – 17:05 – 17:05

• End of Conference – 17:05 – 17:05

Speakers

Dean Calhoun
President, CEO, Affygility Solutions, USA

Felix Tchindo
Occupational Health, Safety, and Environment Manager, Pfizer

Senior Representative CTS Europe Ltd.
CTS Europe Ltd.

Senior Representative FPS
FPS

Senior Representative BSP Pharmaceuticals
BSP Pharmaceuticals,

Jayen Diyora
Sr. Manager, Cleaning Validation, Bristol Myers Squibb

Sree Kurup
Associate Director, Boehringer Ingelheim

Bhakti Halkude
Associate Director, Head of Drug Product, CONTINUUS Pharmaceuticals

Managing Director SafeBridge Consultants

Connor Habib
Project Lead, Bristol-Myers Squibb
For more information about this conference visit https://www.researchandmarkets.com/r/74eyx4

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected] 
 
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
 
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

 

View original content:https://www.prnewswire.com/news-releases/high-potent-medicines-conference-bringing-solutions-to-challenges-in-advanced-high-potent-medicines-boston-ma-united-states—october-19-20-2023-301883031.html

SOURCE Research and Markets